Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells

DJ MacEwan and G Milligan

Institute of Biomedical and Life Sciences, University of Glasgow, Scotland, UK.

Neuroblastoma X glioma hybrid NG108-15 cells were transfected to express stably either the wild-type human beta2-adrenoceptor or a constitutively active mutant (CAM) version of this receptor. Basal adenylyl cyclase activity in cells expressing the CAM beta2- adrenoceptor correlated well with the level of expression of the receptor and was substantially greater than that in cells expressing the wild-type beta2-adrenoceptor. The CAM beta2-adrenoceptor displayed higher affinity for the agonist isoprenaline than the wild-type receptor but not for the antagonist alprenolol or the inverse agonist betaxolol. Pretreatment of cells harboring the CAM beta2-adrenoceptor with betaxolol resulted in a large (4-7-fold within 24 hr) up- regulation in levels of this receptor. This was not observed after exposure of the CAM beta2-adrenoceptor-expressing cells to alprenolol, and a much smaller effect of betaxolol was produced in cells expressing the wild-type receptor. Betaxolol-mediated up-regulation of the CAM beta2-adrenoceptor was both time and concentration dependent. However, this up-regulation did not result in a substantial alteration in the cellular distribution profile of the receptor. Half-maximal up- regulation of the CAM beta2-adrenoceptor required concentrations of betaxolol similar to those needed to cause half-maximal inhibition of basal adenylyl cyclase activity, indicating the receptor up-regulation is associated with the inverse agonist properties of this compound. Despite the large up-regulation of CAM beta2-adrenoceptor levels, treatment with betaxolol did not significantly alter levels of the G protein that couples to this receptor (G(Salpha)). After sustained treatment with betaxolol, Northern analyses did not demonstrate up- regulation of either CAM beta2-adrenoceptor or G(Salpha) mRNA, and up- regulation of the receptor was prevented by cotreatment of the cells with cycloheximide. These data indicate that the up-regulation of the receptor by betaxolol is likely to reflect an increase in translational efficiency of existing mRNA and/or stabilization of the receptor polypeptide from proteolytic degradation and indicate that such effects can be produced by inverse agonists but not by neutral antagonists.

Volume 50, Issue 6, pp. 1479-1486, 12/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				G. Liu, J.-P. Fortin, M. Beinborn, and A. S. Kopin Four Missense Mutations in the Ghrelin Receptor Result in Distinct Pharmacological Abnormalities J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1036 - 1043. [Abstract] [Full Text] [PDF]

				S. Osawa, M. Kajimura, S. Yamamoto, M. Ikuma, C. Mochizuki, H. Iwasaki, A. Hishida, and S. Terakawa Alteration of intracellular histamine H2 receptor cycling precedes antagonist-induced upregulation Am J Physiol Gastrointest Liver Physiol, November 1, 2005; 289(5): G880 - G889. [Abstract] [Full Text] [PDF]

				G. Pineyro, M. Azzi, A. deLean, P. W. Schiller, and M. Bouvier Reciprocal Regulation of Agonist and Inverse Agonist Signaling Efficacy upon Short-Term Treatment of the Human {delta}-Opioid Receptor with an Inverse Agonist Mol. Pharmacol., January 1, 2005; 67(1): 336 - 348. [Abstract] [Full Text] [PDF]

				T. Kenakin Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism Mol. Pharmacol., January 1, 2004; 65(1): 2 - 11. [Abstract] [Full Text] [PDF]

				F.-Y. Zeng, A. J. McLean, G. Milligan, M. Lerner, D. T. Chalmers, and D. P. Behan Ligand Specific Up-Regulation of a Renilla reniformis Luciferase-Tagged, Structurally Unstable Muscarinic M3 Chimeric G Protein-Coupled Receptor Mol. Pharmacol., December 1, 2003; 64(6): 1474 - 1484. [Abstract] [Full Text] [PDF]

				V. Chaipatikul, L. J. Erickson-Herbrandson, H. H. Loh, and P.-Y. Law Rescuing the Traffic-Deficient Mutants of Rat {micro}-Opioid Receptors with Hydrophobic Ligands Mol. Pharmacol., July 1, 2003; 64(1): 32 - 41. [Abstract] [Full Text] [PDF]

				A. J. McLean, F.-Y. Zeng, D. Behan, D. Chalmers, and G. Milligan Generation and Analysis of Constitutively Active and Physically Destabilized Mutants of the Human beta 1-Adrenoceptor Mol. Pharmacol., September 1, 2002; 62(3): 747 - 755. [Abstract] [Full Text] [PDF]

				H. Lavreysen, E. Le Poul, P. Van Gompel, L. Dillen, J. E. Leysen, and A. S. J. Lesage Supersensitivity of Human Metabotropic Glutamate 1a Receptor Signaling in L929sA Cells Mol. Pharmacol., May 1, 2002; 61(5): 1244 - 1254. [Abstract] [Full Text] [PDF]

				S. Miserey-Lenkei, C. Parnot, S. Bardin, P. Corvol, and E. Clauser Constitutive Internalization of Constitutively Active Angiotensin II AT1A Receptor Mutants Is Blocked by Inverse Agonists J. Biol. Chem., February 15, 2002; 277(8): 5891 - 5901. [Abstract] [Full Text] [PDF]

				J. Li, C. Chen, P. Huang, and L.-Y. Liu-Chen Inverse Agonist Up-Regulates the Constitutively Active D3.49(164)Q Mutant of the Rat {micro}-Opioid Receptor by Stabilizing the Structure and Blocking Constitutive Internalization and Down-Regulation Mol. Pharmacol., November 1, 2001; 60(5): 1064 - 1075. [Abstract] [Full Text]

				R. A. Bakker, S. B. J. Schoonus, M. J. Smit, H. Timmerman, and R. Leurs Histamine H1-Receptor Activation of Nuclear Factor-kappa B: Roles for Gbeta gamma - and Galpha q/11-Subunits in Constitutive and Agonist-Mediated Signaling Mol. Pharmacol., November 1, 2001; 60(5): 1133 - 1142. [Abstract] [Full Text] [PDF]

				G. Pineyro, M. Azzi, A. De Lean, P. Schiller, and M. Bouvier Short-Term Inverse-Agonist Treatment Induces Reciprocal Changes in delta -Opioid Agonist and Inverse-Agonist Binding Capacity Mol. Pharmacol., October 1, 2001; 60(4): 816 - 827. [Abstract] [Full Text] [PDF]

				A. A. Coutts, S. Anavi-Goffer, R. A. Ross, D. J. MacEwan, K. Mackie, R. G. Pertwee, and A. J. Irving Agonist-Induced Internalization and Trafficking of Cannabinoid CB1 Receptors in Hippocampal Neurons J. Neurosci., April 1, 2001; 21(7): 2425 - 2433. [Abstract] [Full Text] [PDF]

				T. KENAKIN Inverse, protean, and ligand-selective agonism: matters of receptor conformation FASEB J, March 1, 2001; 15(3): 598 - 611. [Abstract] [Full Text] [PDF]

				P. A. Stevens, N. Bevan, S. Rees, and G. Milligan Resolution of Inverse Agonist-Induced Up-Regulation from Constitutive Activity of Mutants of the alpha 1b-Adrenoceptor Mol. Pharmacol., August 1, 2000; 58(2): 438 - 448. [Abstract] [Full Text]

				A. J. McLean, N. Bevan, S. Rees, and G. Milligan Visualizing Differences in Ligand Regulation of Wild-Type and Constitutively Active Mutant beta 2-Adrenoceptor-Green Fluorescent Protein Fusion Proteins Mol. Pharmacol., December 1, 1999; 56(6): 1182 - 1191. [Abstract] [Full Text]

				N. Dzimiri Regulation of beta -Adrenoceptor Signaling in Cardiac Function and Disease Pharmacol. Rev., September 1, 1999; 51(3): 465 - 502. [Abstract] [Full Text] [PDF]

				K. A. Berg, B. D. Stout, J. D. Cropper, S. Maayani, and W. P. Clarke Novel Actions of Inverse Agonists on 5-HT2C Receptor Systems Mol. Pharmacol., May 1, 1999; 55(5): 863 - 872. [Abstract] [Full Text]

				M. Portier, M. Rinaldi-Carmona, F. Pecceu, T. Combes, C. Poinot-Chazel, B. Calandra, F. Barth, G. L. Fur, and P. Casellas SR 144528, an Antagonist for the Peripheral Cannabinoid Receptor that Behaves as an Inverse Agonist J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 582 - 589. [Abstract] [Full Text]

				M. Rinaldi-Carmona, A. Le Duigou, D. Oustric, F. Barth, M. Bouaboula, P. Carayon, P. Casellas, and G. Le Fur Modulation of CB1 Cannabinoid Receptor Functions after a Long-Term Exposure to Agonist or Inverse Agonist in the Chinese Hamster Ovary Cell Expression System J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1038 - 1047. [Abstract] [Full Text]